Shared on25 Oct 25Fair value Increased 0.73%
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.
Shared on10 Oct 25Fair value Increased 1.12%
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.
Shared on04 Sep 25Fair value Increased 0.43%
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.
Shared on30 Apr 25Fair value Increased 0.37%
AnalystConsensusTarget has increased revenue growth from 2.8% to 3.2%.
Shared on23 Apr 25Fair value Increased 1.19%
AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.
Shared on16 Apr 25Fair value Increased 0.90%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.036%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.46%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 0.81%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Decreased 5.61%
AnalystConsensusTarget has increased revenue growth from 2.2% to 2.6% and increased profit margin from 26.6% to 29.6%.